All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @brianna.curated on TikTok · 56s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @brianna.curated's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm doing my first injection of the sime-a-guitide.
  2. 0:04I really don't know how to say it.
  3. 0:07I had to take a little pause because I could not get it in,
  4. 0:11but it is now in, this is a V12 compound.
  5. 0:14I'm going to put it in the stomach right here.
  6. 0:18So I'm just going to clean the area with an alcohol pad.
  7. 0:52This is day one, day one.

@brianna.curated's GLP-1 journey intro, fact-checked

brianna

TikTok creator

11.5K viewsWatch on TikTok

Quick answer

The creator administered what she described as a 'V12 compound' semaglutide injection into the abdomen on day one of a self-documented weight loss journey, using correct site preparation with an alcohol pad. The designation 'V12' is not a recognized clinical or regulatory label, and the product appears to be a compounded semaglutide formulation rather than an FDA-approved brand. No dose, prescriber, or clinical oversight was mentioned in the video.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @brianna.curated's GLP-1 journey intro, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@brianna.curated's GLP-1 journey intro, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@brianna.curated's GLP-1 journey intro, fact-checked" from brianna. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator administered what she described as a 'V12 compound' semaglutide injection into the abdomen on day one of a self-documented weight loss journey, using correct site preparation with an alcohol pad.

The reason this review is not generic is the source wording and the canonical claim label "glp1 i said i would share the journey with you all so here i am i." In this clip, the useful excerpt is: "I'm doing my first injection of the sime-a-guitide." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The FDA issued a 2024 safety communication warning that compounded semaglutide using salt forms such as semaglutide acetate or sodium has not been tested for human safety or efficacy.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator administered what she described as a 'V12 compound' semaglutide injection into the abdomen on day one of a self-documented weight loss journey, using correct site preparation with an alcohol pad.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator administered what she described as a 'V12 compound' semaglutide injection into the abdomen on day one of a self-documented weight loss journey, using correct site preparation with an alcohol pad. The designation 'V12' is not a recognized clinical or regulatory label, and the product appears to be a compounded semaglutide formulation rather than an FDA-approved brand. No dose, prescriber, or clinical oversight was mentioned in the video.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found subcutaneous semaglutide 2.4 mg weekly produced approximately 14.9 percent mean body weight reduction over 68 weeks, establishing the drug's legitimate clinical profile.
  • The FDA issued a 2024 safety communication warning that compounded semaglutide using salt forms such as semaglutide acetate or sodium has not been tested for human safety or efficacy.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found subcutaneous semaglutide 2.4 mg weekly produced approximately 14.9 percent mean body weight reduction over 68 weeks, establishing the drug's legitimate clinical profile.
  • The FDA issued a 2024 safety communication warning that compounded semaglutide using salt forms such as semaglutide acetate or sodium has not been tested for human safety or efficacy.
  • 'V12 compound' is not a clinical, regulatory, or pharmacological designation. Patients should always ask their compounding pharmacy for the exact active ingredient form and concentration.
  • Abdominal subcutaneous injection is an appropriate site for semaglutide per Wegovy prescribing information, and alcohol pad preparation before injection is correct technique.
  • Compounded semaglutide is not FDA-approved and is not demonstrated to be equivalent to Wegovy or Ozempic. Treating them as interchangeable is not supported by regulatory or clinical evidence.
  • Common early side effects documented in STEP trials include nausea, vomiting, and diarrhea, affecting a significant portion of participants, and are most pronounced during dose escalation.
  • Anyone using compounded semaglutide should verify the compounding pharmacy holds 503A or 503B accreditation and should have a licensed clinician monitoring their treatment plan.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @brianna.curated actually say?

Brianna documented her first injection of what she called "the sime-a-guitide" and identified it as a "V12 compound." That second detail is the one worth paying attention to. She showed herself cleaning the injection site on her stomach with an alcohol pad before administering the shot, framing the whole thing as day one of a weight loss journey she plans to document publicly.

The mispronunciation is not a problem. Semaglutide is genuinely difficult to say and most people who take it stumble over the name. The "V12 compound" label, however, is not a standard clinical designation. It almost certainly refers to a compounded semaglutide formulation, but that shorthand tells viewers nothing about the dose, the salt form, or the compounding pharmacy's quality standards. That ambiguity matters more than she probably realizes.

Does the science back this up?

Semaglutide itself has strong evidence behind it. The STEP trials, published between 2021 and 2022 in the New England Journal of Medicine, showed subcutaneous semaglutide 2.4 mg weekly producing average weight loss of around 15 percent of body weight over 68 weeks in adults with obesity. That is real, replicated data.

What the science does not support is treating compounded semaglutide as equivalent to the FDA-approved product. The FDA has issued multiple warnings, including a 2024 safety communication, about compounded semaglutide products that use semaglutide salts (like semaglutide acetate or sodium) rather than the base form used in Wegovy and Ozempic. These salt forms have not been tested for safety or efficacy in humans. The "V12" label appears nowhere in peer-reviewed literature or FDA labeling, and that alone should prompt questions about what is actually in the vial.

What did they get wrong (or right)?

She got the injection technique directionally right. Subcutaneous injection into the abdomen is a standard and appropriate site for semaglutide, as confirmed in the prescribing information for Wegovy. Cleaning with an alcohol pad before injection is also correct clinical practice.

What she got wrong, or at least incomplete, is the framing of a "V12 compound" as though it is a straightforward starting point. Compounded semaglutide is not a regulated drug product. The FDA placed semaglutide on its shortage list, which temporarily allowed compounding, but in early 2025 the agency moved to remove it, citing the shortage as resolved. Viewers who see this video and interpret it as a green light for any compounded semaglutide product are missing critical context. There is also no acknowledgment of who prescribed this, what dose she is starting on, or whether she is being monitored clinically, all of which matter for safety.

What should you actually know?

Compounded semaglutide is not the same as Wegovy or Ozempic, and calling it a "V12 compound" does not clarify anything meaningful about what is in the syringe. If you are considering semaglutide, the form of the drug, the compounding pharmacy's accreditation, and whether a licensed clinician is overseeing your care are not optional details.

The abdominal injection site Brianna chose is appropriate. Semaglutide can also be injected in the thigh or upper arm. Rotating sites is generally recommended to reduce local reactions. The alcohol pad step is correct.

  • Always confirm your compounding pharmacy holds 503A or 503B accreditation from a state board of pharmacy.
  • Ask specifically whether the product uses semaglutide base, not a salt form like semaglutide acetate.
  • A telehealth provider should be reviewing your baseline labs, contraindications, and titration schedule before you inject anything.
  • Side effects in the STEP trials (Wilding et al., 2021, NEJM) included nausea, vomiting, and diarrhea in a significant portion of participants, most pronounced in early weeks.

Documenting a weight loss journey publicly takes courage. But framing a compounded injectable as simply "day one" without any safety context can mislead the 11,000-plus people watching who may not know the difference between a regulated drug and a compounded one.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

brianna · TikTok creator

11.5K views on this video

I said I would share the journey with you all so here I am I am so excited and nervous about sharing this journey with you all. This is a safe zone so please keep all of your negative comments and tho

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found subcutaneous semaglutide 2.4 mg weekly produced approximately 14.9 percent mean body weight reduction over 68 weeks, establishing the drug's legitimate clinical profile.

What does the video say about the fda?

The FDA issued a 2024 safety communication warning that compounded semaglutide using salt forms such as semaglutide acetate or sodium has not been tested for human safety or efficacy.

What does the video say about 'v12 compound'?

'V12 compound' is not a clinical, regulatory, or pharmacological designation. Patients should always ask their compounding pharmacy for the exact active ingredient form and concentration.

What does the video say about abdominal subcutaneous injection?

Abdominal subcutaneous injection is an appropriate site for semaglutide per Wegovy prescribing information, and alcohol pad preparation before injection is correct technique.

What does the video say about compounded semaglutide?

Compounded semaglutide is not FDA-approved and is not demonstrated to be equivalent to Wegovy or Ozempic. Treating them as interchangeable is not supported by regulatory or clinical evidence.

What does the video say about common early side effects documented in step trials include nausea,?

Common early side effects documented in STEP trials include nausea, vomiting, and diarrhea, affecting a significant portion of participants, and are most pronounced during dose escalation.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by brianna, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.